【作者】 张贝贝； 何春晓； 宋正波； 娄广媛； 余新民； 赵珺； 石志永； 张沂平；

【Author】 ZHANG Bei-bei~(1,2),HE Chun-xiao~2,SONG Zheng-bo~2,LOU Guangyuan~2,YU Xin-min~2,ZHAO Jun~2, SHI Zhi-yong~2,ZHANG Yi-ping~2 (1.Zhejiang Chinese Medical University,the Second Clinical Medical College,Hangzhou 310053,China; 2.Department of Medical Oncology,Zhejiang Cancer Hospital,Hangzhou 310022,China)

【机构】 浙江省肿瘤医院；

【摘要】 [目的]埃克替尼在复治晚期肺腺癌患者的近期疗效与安全性。[方法]分析2011年8月～2012年2月在浙江省肿瘤医院就诊的51例曾经接受过一线或一线以上化疗方案治疗失败的Ⅳ期的肺腺癌患者,给予埃克替尼治疗(125mg口服,每天3次)直至疾病进展,评价疗效与安全性,用Kaplan-Meier法进行生存分析和比较。[结果]在51例患者中12例患者达到部分缓解(partial response,PR)(23.5%),27例患者达到疾病稳定(stable disease,SD)(52.9%),客观缓解率(obiective response rate,ORR)达到23.5%,疾病控制率(disease control rate,DCR)达到76.5%。51例可评价的患者中位无进展生存期(median progression-free survival,mPFS)为5.13个月(95%CI,0.41～9.9),患者自服用埃克替尼直至死亡的中位生存期(median overall survival,mOS)为12.47个月(95%CI,10.06～14.88)。常见的副反应为皮疹和腹泻,大部分患者的皮疹和腹泻是轻到中度,可自行缓解。[结论]埃克替尼可以有效治疗复治晚期肺腺癌患者,且耐受性良好。更多还原

【Abstract】 [Purpose]To evaluate the efficacy and side effects of Icotinib Hydrochloride in patients with advanced adenocarcinoma lung cancer.[Methods]From August 2011-February 2012,51 advanced adenocarcinoma lung cancer patients who had progressed after chemotherapy accept icotinib were retrospectively reviewed (125mg,po,tid),Kaplan-Meier was used to analyze survival and comparison.[Results]Among the 51 patients,12 patients got partial response(23.5%),27 stable disease(52.9%).The objective response rate was 23.5%and disease control rate including both tumor response and stable disease was76.5%.Among the 51 patients,progression-free survival times was 5.13 month(95%CI,0.41～9.9).The OS of patients since starting the treatment of Icotinib Hydrochloride was 12.47 month(95%CI,10.06～14.88).The main toxicity of Icotinib Hydrochloride was skin toxicity(rash) and diarrhea.The majority of patients with rash and diarrhea reached a light or moderate degree.[Conclusions]Icotinib Hydrochloride demonstrates significant antitumor activity and a favorable tolerability profile in adenocarcinoma lung cancer.更多还原